53 results on '"Arban, Roberto"'
Search Results
2. Investigating neuropsychological and reward-related deficits in a chronic corticosterone-induced model of depression
3. Dopamine modulating agents alter individual subdomains of motivation-related behavior assessed by touchscreen procedures
4. Symptomatic and preventive effects of the novel phosphodiesterase-9 inhibitor BI 409306 in an immune-mediated model of neurodevelopmental disorders
5. Effects of pro‐depressant and immunomodulatory drugs on biases in decision‐making in the rat judgement bias task
6. Whole-brain signatures of functional connectivity after bidirectional modulation of the dopaminergic system in mice
7. Preclinical validation of the micropipette-guided drug administration (MDA) method in the maternal immune activation model of neurodevelopmental disorders
8. T178. MICROPIPETTE-GUIDED DRUG ADMINISTRATION (MDA) METHOD AS A NOVEL PHARMACOLOGICAL TREATMENT METHOD IN MICE: PRECLINICAL VALIDATION USING RISPERIDONE IN THE MATERNAL IMMUNE ACTIVATION MODEL OF NEURODEVELOPMENTAL DISORDERS
9. S31. ENHANCEMENT OF SYNAPTIC PLASTICITY BY COMBINATION OF PDE2 AND PDE9 INHIBITION PRESUMABLY VIA PRE- AND POST-SYNAPTIC MECHANISMS
10. S188. The Phosphodiesterase-9 Inhibitor BI 409306 Attenuates Social Interaction and Dopaminergic Deficits in Adult Offspring of poly(I:C)-Based Maternal Immune Activation Neurodevelopmental Mouse Model
11. F21. THE PHOSPHODIESTERASE-9 INHIBITOR BI 409306 ATTENUATES SOCIAL INTERACTION AND DOPAMINERGIC DEFICITS IN ADULT OFFSPRING OF POLY(I:C)-BASED MATERNAL IMMUNE ACTIVATION NEURODEVELOPMENTAL MOUSE MODEL
12. F196. Transgenic Overexpression of the Type III Isoform of Neuregulin 1 in Mice Induces Abnormalities on Auditory Event Related EEG Biomarkers Related to Schizophrenia Accompanied by Reduction of Parvalbumin Positive Interneurons in the Prefrontal Cortex
13. S141. TRANSGENIC OVEREXPRESSION OF THE TYPE III ISOFORM OF NEUREGULIN 1 IN MICE INDUCES ABNORMALITIES ON AUDITORY EVENT RELATED EEG BIOMARKERS RELATED TO SCHIZOPHRENIA
14. Antimanic Efficacy of a Novel Kv3 Potassium Channel Modulator
15. 669. GPR52 Agonists Represent a Novel Approach to Treat Cognitive Deficits Associated with Schizophrenia
16. P4‐010: Improving Cognitive Function in Rodents Via Increasing Glycine Levels in Brain by the Novel Glycine Transporter‐1 Inhibitor BI 425809
17. GSK356278, a Potent, Selective, Brain-Penetrant Phosphodiesterase 4 Inhibitor That Demonstrates Anxiolytic and Cognition-Enhancing Effects without Inducing Side Effects in Preclinical Species
18. Poster #M15 PRE-SYNAPTIC LOCALIZATION OF PDE2 ENZYME AND PHARMACOLOGICAL CHARACTERIZATION OF THE PDE2 INHIBITOR PF-999 IN MODELS RELATED TO COGNITIVE SYMPTOMS OF SCHIZOPHRENIA
19. Distinct receptor subtypes mediate arginine vasopressin-dependent ACTH release and intracellular calcium mobilization in rat pituitary cells
20. Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats
21. Strain-specific outcomes of repeated social defeat and chronic fluoxetine treatment in the mouse
22. Different susceptibility to social defeat stress of BalbC and C57BL6/J mice
23. The characterization of a novel V1b antagonist lead series
24. 5-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2(1H)-quinolinones and 3,4-dihydro-2(1H)-quinolinones: Dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors. Part 3
25. Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: Novel, potent, and selective series of Vasopressin1b receptor antagonists
26. Design and Synthesis of Novel Tricyclic Benzoxazines as Potent 5-HT1A/B/D Receptor Antagonists Leading to the Discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045)
27. 6-(3,4-Dichlorophenyl)-1-[(Methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: A New Potent and Selective Triple Reuptake Inhibitor
28. 1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: A New Series of Potent and Selective Triple Reuptake Inhibitors
29. Alterations of behavioral and endocrinological reactivity induced by 3 brief social defeats in rats: Relevance to human psychopathology
30. Synthesis and Pharmacological Characterization of Novel Druglike Corticotropin-Releasing Factor 1 Antagonists
31. Dihydropyrrole[2,3-d]pyridine Derivatives as Novel Corticotropin-Releasing Factor-1 Antagonists: Mapping of the Receptor Binding Pocket by in Silico Docking Studies
32. Heteroaryl-Substituted 4-(1H-pyrazol-1-yl)-5,6-dihydro-1H-pyrrolo[2,3-d]pyrimidine Derivatives as Potent and Selective Corticotropin-Releasing Factor Receptor-1 Antagonists
33. V1b Receptors: New Probes for Therapy
34. Cyclopenta[d]pyrimidines and Dihydropyrrolo[2,3‐d]pyrimidines as Potent and Selective Corticotropin‐Releasing Factor 1 Receptor Antagonists
35. SB-649915-B, a Novel 5-HT1A/B Autoreceptor Antagonist and Serotonin Reuptake Inhibitor, is Anxiolytic and Displays Fast Onset Activity in the Rat High Light Social Interaction Test
36. Anxiolytic-like effect of the selective Neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze
37. Conditioning properties of social subordination in rats: Behavioral and biochemical correlates of anxiety
38. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): In vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity
39. Single exposure to social defeat increases corticotropin-releasing factor and glucocorticoid receptor mRNA expression in rat hippocampus
40. Selectivity of d[Cha4 ]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b /oxytocin receptor antagonist
41. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania
42. Expression analysis of brain-derived neurotrophic factor (BDNF) mRNA isoforms after chronic and acute antidepressant treatment
43. Enantiomerically pure tetrahydroquinoline derivatives as in vivo potent antagonists of the glycine binding site associated to the NMDA receptor
44. Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse
45. Regional changes in the contralateral ?healthy? hemisphere after ischemic lesions evaluated by quantitative T2 parametric maps
46. The neuroprotective activity of the glycine receptor antagonist GV150526: an in vivo study by magnetic resonance imaging
47. Regional Cerebral Blood Volume Mapping after Ischemic Lesions
48. Characterization of [3H]-imidazenil binding to rat brain membranes
49. A derivative of a rigid glutamate analog protects the retina from excitotoxicity
50. Trans-azetidine-2, 4-dicarboxylic acid activates neuronal metabotropic receptors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.